Icu Medical Inc
Icu Medical Inc (ICUI) is listed on NASDAQ and classified in Medical Instruments & Supplies, part of the Healthcare sector. It is headquartered in San Clemente, United States and has 13,000 employees. The company is worth $4.21B and trades at 134.7x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $2.23B in fiscal 2025, down 6.3% from the year before. Net income was $732K. The share price is 12.7% below its 52-week high of $192.85. 4 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Ken Griffin (Citadel Advisors), at $78.61M. In that quarter, 3 of them opened or added to the position and 1 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▼ -27.9% over 5Y.
today you would have $696.15▼ -30.4%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 19 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $142.67 | $155.17 | $99.74 | $157.48 | $237.34 | $214.49 | $187.12 | $229.63 | $216.00 | $147.35 | $112.78 | $81.90 | $63.71 | $60.93 | $45.00 | $36.50 | $36.44 |
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Median P/E of 24.3 among peers in the sector.
Median P/E of 39.9 across this company’s own years on record.
Cash flow growing 5.0% a year for 10 years, discounted at 10%, then 2.5% forever.
Sector median of 14.1x operating profit, less net debt. Banks have no EBITDA.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| INDVIndivior Pharmaceuticals, Inc. | $35.33 | 12.7x | — | 0.00% | — | $4.17B |
| ITGRInteger Holdings Corp | $126.56 | 34.6x | 2.5x | 0.00% | 7.50% | $4.3B |
| EWTXEdgewise Therapeutics, Inc. | $39.99 | — | 9.6x | 0.00% | -38.03% | $4.34B |
| ARQTArcutis Biotherapeutics, Inc. |
| $33.14 |
| $36.01 |
| P/E | 39.9x | 4755.7x | — | — | — | 50.1x | 53.4x | 39.9x | 172.7x | 65.7x | 40.3x | 41.3x | 48.8x | 24.0x | 21.8x | 14.3x | 16.9x | 21.8x | 19.8x | 23.8x |
| P/S | 2.9x | 1.6x | 1.6x | 1.1x | 1.7x | 4.3x | 3.6x | 3.1x | 3.4x | 3.4x | 6.3x | 5.3x | 4.1x | 3.1x | 2.8x | 2.1x | 1.8x | 2.2x | 2.4x | 2.9x |
| P/B | 2.3x | 1.7x | 1.9x | 1.1x | 1.8x | 3.5x | 3.0x | 2.8x | 3.7x | 3.6x | 3.6x | 3.1x | 2.5x | 2.1x | 2.3x | 2.0x | 1.8x | 1.9x | 1.9x | 2.6x |
| EPS | $0.03 | -$4.83 | -$1.23 | -$3.11 | $4.74 | $4.02 | $4.69 | $1.33 | $3.29 | $3.66 | $2.73 | $1.68 | $2.65 | $2.80 | $3.15 | $2.16 | $1.67 | $1.67 | $1.51 |
| Profit margin | 8.52% | 0.03% | -4.94% | -1.31% | -3.26% | 7.84% | 6.83% | 7.98% | 2.06% | 5.31% | 16.63% | 13.17% | 8.52% | 12.88% | 13.03% | 14.78% | 10.58% | 10.91% | 11.87% | 12.27% |
| ROE | 7.34% | 0.03% | -5.99% | -1.40% | -3.55% | 6.38% | 5.78% | 7.34% | 2.28% | 5.73% | 9.56% | 7.76% | 5.18% | 8.70% | 10.56% | 13.93% | 11.01% | 9.48% | 9.60% | 10.79% |
Median of the years shown; P/E years above 200x are left out.
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
5 methods answered, across 3 families.
Room for errors in the reported numbers.
-67.6% from the average.
Models, not forecasts, and not investment advice. How each formula works →
| $32.20 |
| 146.4x |
| 18.3x |
| 0.00% |
| 15.86% |
| $4.05B |
| DNTHDianthus Therapeutics, Inc. | $78.53 | — | 3.7x | 0.00% | -26.07% | $4.39B |
| RLAYRelay Therapeutics, Inc. | $18.34 | — | 4.5x | 0.00% | -36.77% | $4.02B |